Does Blue Cross Blue Shield Cover Allergy Testing?

Blue Cross Blue Shield does cover allergy testing when a physician documents that it is medically necessary, but the tests allowed, the quantity limits, and the out-of-pocket cost depend on which state affiliate issues the plan and the details of the member’s benefit contract. BCBS operates as a federation of independent companies, so there is no single national policy; each affiliate writes its own clinical guidelines around broadly similar medical standards.

Which Allergy Tests Are Typically Covered

Most BCBS affiliates cover the same core categories of testing when a physician orders them and the chart documents allergic symptoms.

  • Skin prick (percutaneous) testing, the standard first-line method, is covered across virtually all BCBS plans for inhalants, foods, insect venom, and certain drugs.
  • Intradermal testing is generally covered as a follow-up when skin prick results come back negative but the physician still suspects an allergy.
  • Patch testing for contact dermatitis is covered, with expanded panels allowed when the dermatitis is persistent and interferes with daily life.
  • Blood-based IgE testing (such as ImmunoCAP) is typically covered only when skin testing cannot be performed — because of severe skin conditions, an inability to stop antihistamines, or a high risk of anaphylaxis from skin testing.
  • Supervised oral food challenges and bronchial challenges (such as methacholine testing for asthma) are covered when other results are inconclusive.

Some affiliates go further. Blue Cross NC also covers photo-patch testing for suspected contact photosensitization, serial dilution endpoint titration for patients at high risk of severe reactions, and double-blind food challenges performed under controlled conditions.

What “Medically Necessary” Actually Means

Testing is not covered as a routine screen. There must be a clinical reason to suspect an allergy, documented in the medical record.

Blue Cross Blue Shield of Michigan requires that testing be performed “in conjunction with a complete medical and immunologic history” and a face-to-face physical examination, and that the allergens tested be “chosen judiciously” based on symptoms and likely exposures. Capital Blue Cross requires that symptoms not be “adequately controlled by empiric conservative therapy” before testing is ordered. Blue Cross of Vermont specifies that testing must target IgE-mediated reactions, and that retesting is not medically necessary if the result will not change the clinical management plan.

Repeat testing needs its own justification. Children with food allergies can be retested to see whether a sensitivity has resolved. Adults who have completed three to five years of venom immunotherapy can be retested to evaluate whether therapy can be stopped. New symptoms suggesting additional sensitizations also qualify. Routine annual retesting with the same allergens, with no new clinical development, is not covered.

How Many Tests Your Plan Will Pay For

Even covered tests come with numerical caps, and the limits vary by affiliate.

Capital Blue Cross in Pennsylvania allows up to 70 percutaneous tests and 40 intradermal tests per benefit period, with an 80-test cumulative cap on serial endpoint titration. Blue Cross Blue Shield of Mississippi caps skin testing at 50 percutaneous and 20 intradermal tests per day, counting each allergen as a test rather than each injection. Blue Cross Blue Shield of Rhode Island sets annual maximums by CPT code — 80 units for standard scratch testing, 90 units for certain intradermal codes, and 40 units for others — and states that retesting with the same allergens should rarely be necessary within three years.

Blood-based IgE caps are tighter. Blue Cross NC covers up to 40 allergen-specific IgE antibodies per year. Blue Cross Blue Shield of Texas and Blue Cross Blue Shield of Illinois each allow 20 per year. Highmark, which covers Pennsylvania, West Virginia, Delaware, and New York, limits in-vitro IgE testing to 36 tests per year and skin testing to 70 percutaneous or 40 intradermal tests per benefit year. Across every plan, the allergens tested must track the patient’s history and likely exposures; blanket screening panels are not supported.

Tests BCBS Will Not Cover

A consistent list of methods is classified as investigational and excluded. These are tests that major medical organizations, including the American Academy of Allergy, Asthma and Immunology and the National Institute of Allergy and Infectious Diseases, have found to lack sufficient evidence of diagnostic accuracy.

  • IgG and IgG4 food sensitivity panels. Anthem cites the European Academy of Allergy and Clinical Immunology position that “food-specific IgG4 does not indicate food allergy or intolerance.” Arkansas Blue Cross, Highmark, and Blue Cross of Florida reach the same conclusion.
  • ALCAT (Antigen Leukocyte Cellular Antibody Test), excluded by Blue Cross NC, Rhode Island, Texas, Illinois, Anthem, and Highmark.
  • Mediator Release Test (MRT). Blue Cross NC notes there are no peer-reviewed studies demonstrating improved outcomes from its use.
  • Cytotoxic food testing.
  • Provocative and neutralization testing (Rinkel test). The Federal Employees Health Benefit Plan BCBS brochure excludes provocative food testing under both its Standard and Basic options.
  • Applied kinesiology.
  • Electrodermal testing (VEGA).
  • Bead-based epitope assays and component-resolved diagnostics such as VeriMAP Peanut Dx, not covered by Blue Cross of Illinois, Blue Cross NC, or Blue Cross of Louisiana.
  • Hair analysis, salivary testing, and stool-based food antibody analysis.

Anthem notes that none of these excluded tests have received FDA-labeled indications for allergy diagnosis.

Referrals, Prior Authorization, and Documentation

Whether you need a referral or prior authorization depends on your plan type, not on allergy testing specifically. Under most BCBS HMO plans, you need a referral from your primary care provider to see an allergist. PPO plans generally do not require referrals for specialist visits. Some services may still require prior authorization regardless of plan type.

Standard allergy skin testing typically does not require prior authorization under the medical policy itself. Documentation is the gatekeeper. If a plan audits the claim later, the physician’s chart notes must show the patient’s clinical history, symptoms, prior treatments, and the reasoning behind each test ordered. Blue Cross NC states it may request medical records to verify necessity and that letters of support alone are not sufficient — the clinical documentation itself must contain the required detail.

Call the number on the back of your member ID card before scheduling. Authorization rules vary plan by plan, and the benefit booklet, not the general medical policy, controls.

What You Will Pay Out of Pocket

What you actually pay turns on your deductible, copay, and coinsurance. There is no standard dollar amount across BCBS.

Under the 2025 BCBS Federal Employee Health Benefit Plan Standard Option, allergy testing, treatment, and sublingual desensitization drugs cost 15% of the plan allowance when using a preferred provider, with the annual deductible applying first. Participating or non-participating providers cost 35%, and non-participating providers may also balance-bill beyond the plan allowance.

Under the FEHB Basic Option, the copay is $35 for a preferred primary care provider and $50 for a preferred specialist. Agents, drugs, or supplies administered during the visit carry a 30% coinsurance. Non-preferred providers are not covered at all under Basic.

Blue Shield of California’s HMO guidelines state that copay amounts are set by each member’s Evidence of Coverage, and that allergy serum (the antigen extract used in immunotherapy) carries a separate copay of 50% of allowed charges.

The most reliable estimate comes from calling the number on your member card or logging in to your plan’s member portal before scheduling.

Coverage for Treatment After a Positive Test

Once allergies are confirmed, most BCBS plans cover subcutaneous immunotherapy (allergy shots) for members whose symptoms cannot be controlled through avoidance or medication alone. Blue Cross NC limits coverage to 180 units in the first year and 120 units per year during maintenance, and requires that shots be given in a setting equipped to handle anaphylaxis.

Sublingual immunotherapy is more limited. Most plans exclude compounded sublingual drops but cover specific FDA-approved tablets: Oralair, Grastek, Ragwitek, and Odactra. Blue Shield of California’s HMO guidelines exclude sublingual allergen administration entirely.

For food allergies, oral immunotherapy is largely investigational. The exception is Palforzia, an FDA-approved peanut allergen powder. Blue Cross Blue Shield of Michigan covers Palforzia when prescribed by or in consultation with an allergist, with a confirmed peanut allergy diagnosis, and when the patient does not have severe uncontrolled asthma or recent life-threatening anaphylaxis. Authorization runs one year at a time. Arkansas Blue Cross classifies other oral and sublingual food immunotherapy as investigational.

If Your Claim Is Denied

Read the denial letter carefully first. The Allergy and Asthma Network points to the most common causes: the insurer concluded the test was not medically necessary, there was a coding error on the provider’s end, or the service was performed out of network.

Then contact the treating physician and ask for supporting documentation, including a letter of medical necessity explaining the diagnosis, why testing was clinically appropriate, and what outcomes were expected. Review your benefit booklet for the specific appeals process and deadlines.

If the internal appeal fails, you can request an external review through your state insurance department or seek help from a patient advocacy organization. Keep copies of all correspondence and track the deadlines closely; most plans enforce strict time limits.